Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Biotechnology

Background:

• Gene therapy aims to treat genetic disorders by delivering therapeutic genes.
• Existing gene therapy methods often lack reversibility and long-term safety assurances.
• Muscle progenitor cells offer a potential platform for sustained therapeutic protein production.

Purpose of the Study:

• To develop a reversible gene therapy approach for producing blood clotting factor IX (FIX).
• To evaluate the efficacy and safety of bioengineered human muscles as a delivery system for FIX.
• To investigate the role of angiogenesis in enhancing therapeutic protein delivery from engineered tissues.

Main Methods:

• Human muscle progenitor cells were transduced with lentiviral vectors to express FIX.
• Engineered cells were differentiated into postmitotic myofibers, forming human bioartificial muscles (HBAMs).
• HBAMs were implanted subcutaneously into immunodeficient mice, and FIX levels were monitored over time.

Main Results:

• Implanted HBAMs secreted biologically active FIX into circulation for over 3 months.
• The engineered FIX underwent necessary posttranslational modifications, indicating cellular functionality.
• HBAMs engineered with vascular endothelial growth factor showed sustained therapeutic FIX levels, linked to angiogenesis.

Conclusions:

• Bioengineered HBAMs provide a viable, reversible gene therapy strategy for sustained FIX production.
• The retrievable nature of HBAMs offers an inherent safety advantage.
• Angiogenesis plays a crucial role in the efficient delivery of therapeutic proteins via tissue-engineered stem cell-based gene therapies.